Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp., a clinical-stage biopharmaceutical company, has announced the appointment of Christopher Cherry as Chief Financial Officer. Cherry brings a wealth of experience, including roles as CFO for various public issuers and positions at major accounting firms. The company expects Cherry to play a key role in driving growth and enhancing shareholder value as BioVaxys advances its immunotherapy-based clinical pipeline.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
